Table II.
List of biomarkers that presented <2 risk ratios compared to the control populations (low and moderate reliable markers).
| Result | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Authors | Biomarker | Endpoint | Condition | HR | 95% CI | No. | Sample | Periods | (Refs.) |
| Jézéquel et al | FTL | MFS | <2.4 | 1.0 | – | 198 | Biopsy | 1980–2000 | (40) |
| >2.4 | 1.3 | 1.10–1.50 (P=0.001) | |||||||
| Harbeck et al | uPA/PAI-1 | DFS | Low | 1.0 | – | 409 | Blood | 1993–1998 | (43) |
| High | 1.84 | 1.1–3.0 (P=0.017) | |||||||
| OS | Low | 1.0 | – | ||||||
| High | 1.85 | 1.1–3.1 (P=0.02) | |||||||
| Villaseñor et al | CRP | OS | <1 mg/l | 1.0 | – | 2,919 | Blood | 1995–2000 | (46) |
| ≥10 mg/l | 1.96 | 1.22–3.13 (P<0.001) | |||||||
| Earl et al | Ch17CEP | OS | Normal | 1.0 | – | 1,762 | Biopsy | 1996–2001 | (50) |
| Duplication | 0.80 | 0.68–0.95 (P=0.009) | |||||||
| Moreno-Aspitia et al | sHER2 | DFS | <15 | 1.0 | – | 2,318 | Blood | 2004–2005 | (55) |
| ≥15 | 2.36 | 1.19–4.70 (P=0.01) | |||||||
| Sun et al | MAD1L1 | OS | Low | 1.0 | – | 461 | Biopsy | 2006 | (57) |
| High | 1.825 | −(P=0.027) | |||||||
| Hartmann et al | PITX2P2 Methylation | TDM | TDM | 1.66 | 1.21–2.28 (P=0.002) | 241 | Biopsy | NA | (66) |
MFS, metastasis-free survival; uPA/PAI-1, urokinase-type plasminogen activator and plasminogen activator type 1 inhibitor; CRP, C-reactive protein; Ch17CEP, Chromosome 17 centromere enumeration probe; sHER2, soluble human epidermal growth factor receptor 2; MAD1L1, mitotic arrest deficient like 1; PITX2P2, methylation of paired-like homeodomain 2; TDM, time to distant metastasis; DFS, disease free survival; OS, overall survival.